argenx Data Highlight Evidence that VYVGART and VYVGART Hytrulo Drive Transformative Outcomes for Patients with Debilitating Autoimmune Disease

April 16, 2024

https://www.globenewswire.com/news-release/2024/04/16/2863272/0/en/argenx-Data-Highlight-Evidence-that-VYVGART-and-VYVGART-Hytrulo-Drive-Transformative-Outcomes-for-Patients-with-Debilitating-Autoimmune-Disease.html

ADHERE data show VYVGART® Hytrulo has potential to be first advancement for CIDP patients in 30 years

Real-world data demonstrate gMG patients able to significantly reduce steroid use over first six months of initiating VYVGART® treatment

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.